+

PE20091106A1 - Vacuna - Google Patents

Vacuna

Info

Publication number
PE20091106A1
PE20091106A1 PE2008002018A PE2008002018A PE20091106A1 PE 20091106 A1 PE20091106 A1 PE 20091106A1 PE 2008002018 A PE2008002018 A PE 2008002018A PE 2008002018 A PE2008002018 A PE 2008002018A PE 20091106 A1 PE20091106 A1 PE 20091106A1
Authority
PE
Peru
Prior art keywords
adenoviric
appe
malaria
vector
protein
Prior art date
Application number
PE2008002018A
Other languages
English (en)
Inventor
Joseph D Cohen
Martine Marchand
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091106(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of PE20091106A1 publication Critical patent/PE20091106A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UN VECTOR ADENOVIRICO DE SIMIO DEFICIENTE DE REPLICACION C7, QUE CODIFICA UNA PROTEINA DEL CIRCUNSPOROZOITO (PROTEINA CS) DE LA ESPECIE PLASMODIUM FALCIPARUM O UN FRAGMENTO DE LA MISMA QUE COMPRENDE LA SECUENCIA DE SEC ID Nº 1 Y SEC ID Nº 3. SE REFIERE TAMBIEN A UNA COMPOSICION DE VACUNA QUE COMPRENDE: 1) EL VECTOR ADENOVIRICO DE SIMIO DEFICIENTE DE REPLICACION C7; 2) UN ANTIGENO DE LA MALARIA RTS,S; Y 3) UN COADYUVANTE TALES COMO MONOFOSFORIL-LIPIDO A 3-DESACILADO (3D-MPL) Y LA SAPONINA QS21, EN DONDE LA FORMULACION ESTA CONTENIDA EN UNA EMULSION DE ACEITE EN AGUA SIENDO UTIL PARA EL TRATAMIENTO O PROFILAXIS DE LA MALARIA
PE2008002018A 2007-12-06 2008-12-04 Vacuna PE20091106A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99280207P 2007-12-06 2007-12-06

Publications (1)

Publication Number Publication Date
PE20091106A1 true PE20091106A1 (es) 2009-08-24

Family

ID=40591828

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008002018A PE20091106A1 (es) 2007-12-06 2008-12-04 Vacuna

Country Status (20)

Country Link
EP (1) EP2227550A2 (es)
JP (1) JP2011505796A (es)
KR (1) KR20100108544A (es)
CN (1) CN101939438A (es)
AR (1) AR069568A1 (es)
AU (1) AU2008333208A1 (es)
BR (1) BRPI0819889A2 (es)
CA (1) CA2707245A1 (es)
CL (1) CL2008003614A1 (es)
CO (1) CO6300795A2 (es)
CR (1) CR11537A (es)
DO (1) DOP2010000164A (es)
IL (1) IL205953A0 (es)
MA (1) MA32003B1 (es)
MX (1) MX2010006207A (es)
PE (1) PE20091106A1 (es)
TW (1) TW200938633A (es)
UY (1) UY31510A1 (es)
WO (1) WO2009071613A2 (es)
ZA (1) ZA201003851B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0815872D0 (en) * 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB201016471D0 (en) * 2010-09-30 2010-11-17 Isis Innovation Viral vector immunogenic compositions
CA2832307A1 (en) * 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CN110687289B (zh) * 2019-10-17 2023-04-18 中国人民解放军陆军军医大学 Fgl2蛋白作为疟疾感染标志物的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
RU2356577C9 (ru) * 2002-10-23 2009-08-10 Глаксосмитклайн Байолоджикалс С.А. Способы вакцинации против малярии
EP1573012B1 (en) * 2002-12-17 2011-11-30 Crucell Holland B.V. Recombinant viral-based malaria vaccines
WO2005063805A1 (en) * 2003-12-23 2005-07-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies against the amino terminus region of circumsporozoite protein prevent the onset of malaria infection
DK2163260T3 (en) * 2004-01-23 2017-06-19 Msd Italia Srl Chimpanzee adenovirus vaccine carriers
US20080131461A1 (en) * 2004-10-14 2008-06-05 Crucell Holland B.V. Malaria Prime/Boost Vaccines
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
US20090110695A1 (en) * 2006-03-27 2009-04-30 Menzo Jans Emko Havenga Compositions Comprising a Recombinant Adenovirus and an Adjuvant
NZ574238A (en) * 2006-07-18 2012-02-24 Glaxosmithkline Biolog Sa Vaccines for malaria
AU2008223951B2 (en) * 2007-03-02 2014-03-27 Glaxosmithkline Biologicals S.A. Novel method and compositions
GB0706914D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors

Also Published As

Publication number Publication date
CO6300795A2 (es) 2011-07-21
EP2227550A2 (en) 2010-09-15
CA2707245A1 (en) 2009-06-11
WO2009071613A3 (en) 2009-08-13
IL205953A0 (en) 2010-11-30
AU2008333208A1 (en) 2009-06-11
WO2009071613A2 (en) 2009-06-11
JP2011505796A (ja) 2011-03-03
CN101939438A (zh) 2011-01-05
AR069568A1 (es) 2010-02-03
DOP2010000164A (es) 2010-07-31
KR20100108544A (ko) 2010-10-07
MA32003B1 (fr) 2011-01-03
CL2008003614A1 (es) 2010-01-15
BRPI0819889A2 (pt) 2015-06-16
UY31510A1 (es) 2009-08-03
CR11537A (es) 2010-08-18
ZA201003851B (en) 2012-11-28
TW200938633A (en) 2009-09-16
MX2010006207A (es) 2010-10-04

Similar Documents

Publication Publication Date Title
EA201792562A1 (ru) Глюкагон и коагонисты гпп-1
MX2021011949A (es) Metodos para el tratamiento de enfermedad de higado graso no alcoholico y/o lipodistrofia.
AR050353A1 (es) Composicion de anticuerpo her2
MX2019007749A (es) Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5.
PE20141166A1 (es) Anticuerpos anti-angptl3 y usos de los mismos
ECSP10010697A (es) Inhibidores de dpp-iv para uso en el tratamiento de nafld
BR112019021824A2 (pt) Vacinas contra a malária e anticorpos de ligação a esporozoítos de plasmódio
PE20140173A1 (es) Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
CL2008002361A1 (es) Uso de un antigeno derivado de la proteina circumesporozoito (cs) de plasmodium falciparum que se expresa en la etapa preeritrocitica de la infeccion por malaria para tratar bebes contra la malaria.
MX2017003121A (es) Formulaciones de anticuerpos.
AR102547A1 (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
EA201791907A1 (ru) Бивалентная вакцина против вируса свиного гриппа
PE20091106A1 (es) Vacuna
MX2017006748A (es) Composiciones de aminoácidos para el tratamiento de síntomas de enfermedades.
UA120999C2 (uk) Естери оксаборолу та їх використання
AR099960A1 (es) Procedimientos y composición farmaceutica para inducir una respuesta inmunitaria
EA201890638A1 (ru) Отклоняющие кислоты, содержащие водорастворимое замедляющее действие средство, а также способы изготовления и применения
EA201001478A1 (ru) Вакцина
BRPI0606614A2 (pt) peptìdeos para distribuição de vacinas na mucosa
PH12018501646A1 (en) Compositions and methods for treating infections
MX391376B (es) Composiciones de la membrana de la cáscara del huevo para usarse en el tratamiento de la cadena ligera kappa del factor nuclear de las células b activadas (nf-kb) en un organismo hospedero.
AR073967A1 (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen al mismo
BRPI0508807A (pt) composição de tratamento capilar, uso de uma composição e método de tratamento de cabelo
EA201200538A1 (ru) Арабиногалактан для повышения приобретенного иммунного ответа
CO2019007671A2 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer

Legal Events

Date Code Title Description
FC Refusal
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载